Oncotelic extends reverse merger deadline with Mosaic ImmunoEngineering to June 30, 2025

Oncotelic Therapeutics, Inc.

Term sheet dated April 26, 2024, originally 90-day term, extended to Dec 31, 2024; now extended to June 30, 2025.
No definitive agreement reached; extension allows continued due diligence and documentation.
Both companies mutually agreed extension is in best interests; transaction remains conditional and not guaranteed.
Extension letter executed December 31, 2024; no other term sheet modifications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.